6th CKD Summit – Chronic Kidney Disease Drug Development
19-21 March, 2024
Boston, MA
ENYO Pharma will attend the 6th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
ASN Kidney Week 2023
2-5 November 2023
Philadelphia, PA
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week
https://www.asn-online.org/education/kidneyweek/
Alport Connect 2023, the annual Alport syndrome patient and family meeting in US
7-8 October, 2023
San Diego, CA
ENYO Pharma is sponsoring and will attend Alport Connect 2023 organized by the American Alport Syndrome Foundation (ASF) to meet patients and their family and present its Phase 2 clinical study planned with Vonafexor in Alport syndrome patients.
Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
ENYO Pharma announces that both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation (ODD) to Vonafexor, our fibrolytic & anti-inflammatory clinical compound, for the treatment of Alport syndrome.
Alport syndrome is a rare kidney disease, a genetic disorder affecting 1 in 5,000-10,000 live births. It is characterized by a progressive loss of kidney function and may result in hearing loss and eye abnormalities.
5th CKD Summit – Chronic Kidney Disease Drug Development
7-9 March, 2023
Boston, MA
ENYO was attending the 5th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
Latest Press Release 